Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Omega-3 fatty acids for bipolar disorder
Your Article Summary
See Latest ArticlesOlanzapine orally disintegrating tablets (Zyprexa Zydis) rapidly improve excitement components in the acute phase of first-episode schizophrenic patients: An open-label prospective study
World Journal of Biological Psychiatry, 09/10/09
Hori H et al. – The results suggest that olanzapine orally disintegrating tablets are effective and well–tolerated for treatment excitement in the acute phase of schizophrenic patients. In addition, it is possible that adherence to medications is improved by using olanzapine orally disintegrating tablets.
Today in Neuro/Psych Pharmacol...keeping you current
Receive free subspecialty "5-minute updates" via email
Is Monotherapy as Good as Polypharmacy in Long-Term Treatment of Bipolar Disorder
Canadian Journal of Psychiatry, 11/16/09
Cardiometabolic Risk of Second-Generation Antipsychotic Medications During First-Time Use in Children and Adolescents
JAMA, 10/28/09
Asenapine versus olanzapine in acute mania: a double-blind extension study
Bipolar Disorders, 10/22/09
Today in Other Psychiatry...keeping you current
Receive free subspecialty "5-minute updates" via email
Is Monotherapy as Good as Polypharmacy in Long-Term Treatment of Bipolar Disorder
Canadian Journal of Psychiatry, 11/16/09
Cardiometabolic Risk of Second-Generation Antipsychotic Medications During First-Time Use in Children and Adolescents
JAMA, 10/28/09
Asenapine versus olanzapine in acute mania: a double-blind extension study
Bipolar Disorders, 10/22/09
Today in Schizophrenia/Psychosis...keeping you current
Receive free subspecialty "5-minute updates" via email
Cardiometabolic Risk of Second-Generation Antipsychotic Medications During First-Time Use in Children and Adolescents
JAMA, 10/28/09
Impact of real-world ziprasidone dosing on treatment discontinuation rates in patients with schizophrenia or bipolar disorder
Schizophrenia Research, 11/18/09
Changes in metabolic syndrome parameters in patients with schizoaffective disorder who participated in a randomized, placebo-controlled trial of topiramate
Asian Journal of Psychiatry, 11/09/09
Sponsor
Article Search
Sponsor